Performance of the resolute zotarolimus‐eluting stent in small vessels

Leon, Martin B.; Serruys, Patrick W.; Neumann, Franz‐Josef; Yeung, Alan C.; Windecker, Stephan; Belardi, Jorge; Silber, Sigmund; Meredith, Ian T.; Widimský, Petr; Saïto, Shigeru; Mauri, Laura

doi:10.1002/ccd.25485

Cited by 22 publications

(22 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, for this study we used RVD ≤2.5 mm to define SV‐PCI . Similar to prior reports, we observed that patients undergoing SV‐PCI were more likely to be older, female and present with a greater burden of cardiovascular risk factors, particularly diabetes mellitus and hypertension . It is, therefore, not surprising that SV‐PCI patients in our study also presented with more coronary lesions and greater vessel tortuosity.…”

Section: Discussionsupporting

confidence: 81%

“…In the era of bare metal stents (BMS) and first‐generation DES, a RVD ≤3 mm has often been used as cut‐off . However, in more recent years, as smaller stent diameters have become available, lower thresholds for RVD (e.g., <2.75 mm or ≤2.5 mm), have more frequently been used to define small vessel PCI . Consequently, for this study we used RVD ≤2.5 mm to define SV‐PCI .…”

Section: Discussionmentioning

confidence: 99%

“…The prevalence of small vessel coronary artery disease (CAD) in patients undergoing percutaneous coronary intervention (PCI) is as high as 50%, depending on its definition and the demographics of the patient population studied . Although there exists no universally accepted definition for small vessel CAD, a reference vessel diameter (RVD) ≤2.5 for the target lesion has often been adopted . Neo‐intimal proliferation and local inflammation that follow PCI result in higher rates of in‐stent restenosis and overall recurrent ischemic events in small vessels .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Small‐vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus‐eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post‐Approval studies

Guedeney

Claessen

Kandzari

et al. 2019

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objective We evaluated 1‐year outcomes after platinum chromium everolimus‐eluting stents (PtCr‐EES) in small versus non‐small coronary arteries within a large, diverse sample of men, women, and minorities. Background There exists limited outcomes data on the use of second‐generation drug‐eluting stent to treat small diameter coronary arteries. Methods We pooled patients from the PLATINUM Diversity and PROMUS Element Plus stent registries. Small‐vessel percutaneous coronary intervention (SV‐PCI) was defined as ≥1 target lesion with reference vessel diameter (RVD) ≤2.5 mm. Endpoints included major adverse cardiac event (MACE; death, myocardial infarction [MI] or target vessel revascularization [TVR]), target vessel failure (TVF; death related to the target vessel, target vessel MI or TVR) and definite/probable stent thrombosis (ST). Multivariable Cox regression was used to risk‐adjust outcomes. Results We included 4,155/4,182 (99%) patients with available RVD, of which 1,607 (39%) underwent small‐vessel PCI. SV‐PCI was not associated with increased MACE (adjHR 1.02; 95%CI 0.81–1.30) or TVF (adjHR 1.07; 95%CI 0.82–1.39). MI risk was lower in white men compared to women and minorities, both in the setting of SV‐PCI (adjHR 0.41; 95%CI 0.23–0.74 and adjHR 0.39; 95%CI 0.20–0.75, respectively) and for non‐SV‐PCI (adjHR 0.61; 95%CI 0.38–0.99 and adjHR 0.45; 95%CI 0.27–0.74, respectively). There was no significant interaction between RVD and sex or minority status for any endpoint. Conclusion In a large diverse contemporary PCI outcomes database, SV‐PCI with PtCr‐EES was not associated with increased MACE or TVR and did not account for the increased MI risk noted in women and minorities compared to white men.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Small‐vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus‐eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post‐Approval studies

Guedeney

Claessen

Kandzari

et al. 2019

Cathet Cardio Intervent

View full text Add to dashboard Cite

show abstract

“…To address the lack of direct long‐term comparative studies of DCB versus new generation DES for SVD treatment, we compared the 4.7–10.1% 2‐year TLF rates observed using everolimus‐ or zotarolimus‐eluting stents with the ones from our current study. These data suggest that even in the era of widespread use of new generation DES, DCBs may still have an important role to play in the treatment of de novo small CAD.…”

Section: Discussionmentioning

confidence: 99%

Two‐year follow‐up of a randomized multicenter study comparing a drug‐coated balloon with a drug‐eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial

Tian

Tang

Qiao

et al. 2020

Cathet Cardio Intervent

View full text Add to dashboard Cite

Objectives To report the clinical outcomes of the RESTORE drug‐coated balloon (DCB; Cardionovum, Bonn, Germany) for treatment of de novo small vessel disease (SVD) beyond 1 year. Background Previous reports have demonstrated the noninferiority of the RESTORE DCB to the RESOLUTE Integrity drug‐eluting stent (DES; Medtronic, Minneapolis, Minnesota) in terms of 9‐month in‐segment percent diameter stenosis. Methods In the prospective, multicenter, noninferiority RESTORE SVD China trial, 230 patients with visually‐estimated reference vessel diameter (RVD) ≥2.25 and ≤2.75 mm were randomized to DCB or DES in a 1:1 ratio stratified by diabetes and number of lesions treated. Furthermore, 32 patients with RVD ≥2.00 and <2.25 mm were enrolled in a nested very small vessel (VSV) registry. Clinical follow‐up were performed at 2 years to evaluate target lesion failure (TLF) in both groups and the VSV cohort. Results Overall, 256 (97.7%) patients (115 and 109 in the DCB and DES groups, respectively, and 32 in the VSV cohort) completed 2 years of follow‐up. There was no significant difference in TLF between the DCB and DES groups (5.2 vs. 3.7%, p = .75). Target lesion revascularization was acceptable at 1 month, 1 year, and 2 years, and did not differ significantly with DCB from that in the DES group (0.9 vs. 0%, p = 1.0, 4.4 vs. 2.6%, p = .72, 5.2 vs. 2.8%, p = .50, respectively). Conclusions Compared to the second‐generation DES, the RESTORE DCB did not increase the risk of clinical outcomes. Late catch‐up phenomen requiring revascularization was not significant in this study.

show abstract

“…The definition of small vessel coronary disease has not been consistent in the literature, with several prior proposed definitions, including ≤3.0-mm 9 , ≤2.75-mm 10 and ≤ 2.5-mm [23]. Subsequent availability of 2.25-mm DES lead to the proposal of the definition of "very small coronary arteries" for coronary vessel lesions amenable to 2.25 mm-DES [10].…”

Section: Discussionmentioning

confidence: 96%

Composite outcomes in 2.25-mm drug eluting stents: a systematic review

Lee

Singh

Ortega

et al. 2015

Cardiovascular Revascularization Medicine

View full text Add to dashboard Cite

Performance of the resolute zotarolimus‐eluting stent in small vessels

Abstract: When used for the treatment of small vessels, the R-ZES appears to provide acceptable clinical results at 2 years when compared to its performance in large vessels.

Cited by 22 publications

References 24 publications

Small‐vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus‐eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post‐Approval studies

Small‐vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus‐eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post‐Approval studies

Two‐year follow‐up of a randomized multicenter study comparing a drug‐coated balloon with a drug‐eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial

Composite outcomes in 2.25-mm drug eluting stents: a systematic review

Contact Info

Product

Resources

About